Under the Paperwork Reduction Act of 1995, no person are required to

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

PTO/SB/17 (12-04v2)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.

Effective on 12/08/2004.

FEE TRANSMITTAL
For FY 2006

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)

	respond to a collection of information unless it displays a valid OMB control number					
Complete if Known						
	Application Number	10/665,522				
	Filing Date	September 22, 2003				
	First Named Inventor	Stamm				
	Examiner Name	Sheikh				
	Art Unit	1615				
	Attorney Docket No.	31672-224622				

METHOD OF PAYMENT (check all that apply)								
Check Credit Card Money Order None Other (please identify):								
X Deposit Account Deposit Account Number: 22-0261 Deposit Account Name: Venable LLP								
For the above-ide	ntified deposit	account, the I	Director is he	ereby authoriz	ed to: (check	all that apply	<i>(</i>)	
x Charge fee(s) indicated be	low		Charge	e fee(s) indica	ited below, e	except for the	he filing fee
Charge any	additional fee(s) or underpa	vment of	x Credit	any overpaym	nente		
fee(s) unde	r 37 CFR 1.16	and 1.17						
FEE CALCULATION	(All the fees	below are o	due upon f	filing or may	be subject	to a surcl	harge.)	
1. BASIC FILING, SEAR	•				5 248415445	FIGN FEE		
		S FEES Small Entity	SEAR	CH FEES Small Entity	EXAMINAT	I ION FEES Small Entity	5	
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees I	Paid (\$)
Utility	300	150	500	250	200	100		
Design	200	100	100	50	130	65		
Plant	200	100	300	150	160	80		
Reissue	300	150	500	250	600	300		
Provisional	200	100	0	0	0	0		
2. EXCESS CLAIM FEES	;							Small Entity
Fee Description							<u>Fee (\$)</u>	<u>Fee (\$)</u>
Each claim over 20 (inclu	•	•					50	25
Each independent claim of	`	ng Reissues)					200	100
Multiple dependent claim	ıs						360	180
Total Olalina	Extra	(¢)	Fee Paid	4 (¢)	8414	ple Depend	lant Claima	
Total Claims - 20 or HP	Claims F	ee (\$) _	reerait	7 (4)			Fee Paid (
HP = highest number of total claims paid for, if greater than 20.								
Indep. Extra								
Claims Fee (\$) Fee Paid (\$)								
3 or HP = x =								
HP = highest number of total claims paid for, if greater than 3.								
3. APPLICATION SIZE FEE								
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50								
sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).								
Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)								
- 100 = /50 (round up to a whole number) x =								
4. OTHER FEE(S) Fees Paid (\$)						Paid (\$)		
Non-English Specific	ation, \$130 fe	e (no small e	ntity discou	nt)				
Other (e.g., late filing	•							
surcharge):		Termina	l Disclaime	er (\$130); IDS	S (\$180)			310
SUBMITTED BY	. /\ \ ^	9	~/ <i>I</i> //	$\overline{}$				
Signature		1		egistration No. Attorney/Agent)	38,898	Telephone	(202) 3	44-4000
Name (Print/Type) Edward	ID Grieff	1 6				Date	lune 1	9 2006

This collection of information is required by 37 CFR 136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 2 and 37 CFR 14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application for its this USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

\$ FW

JUN 1 9 7006 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Stamm et al

Application No. 10/665,522

Group Art Unit: 1615

Filed: September 22, 2003

Examiner: Sheikh

For:

Fenofibrate Compositions Having Enhanced Bioavailability

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Transmittal Letter

Enclosed herewith for appropriate action by the US Patent Office are the following:

- 1. Terminal Disclaimer.
- 2. Information Disclosure Statement, PTO-1449 Form, and a copy of the required cited references.

The Commissioner is authorized to charge the fee of \$310 (including \$130 for the Terminal Disclaimer and \$180 for the IDS) to Deposit Account No. 22-0261. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account

No. 22-0261.

Edward D. Grieff

Respectfully submitted,

Registration No. 38,898

Date: June 19, 2006

Venable LLP

575 7th Street, NW

Washington, DC 20004 Phone: 202-344-4382



the Application of: Stamm et al

Application No. 10/665,522 Group Art Unit: 1615

Filed: September 22, 2003 Examiner: Sheikh

For: Fenofibrate Compositions Having Enhanced Bioavailability

Commissioner of Patents PO Box 1450 Alexandria, VA 22313-1450

Terminal Disclaimer

Laboratoires Fournier, S.A. certifies that it is the owner of the entire right, title and interest in Application No. 10/665,522 filed September 22, 2003, entitled "Fenofibrate Compositions Having Enhanced Bioavailability" (hereafter the "above-identified application") by virtue of an Assignment recorded in the US Patent and Trademark Office on June 17, 1998, at Reel 9260, Frame 0797.

Laboratoires Fournier, S.A. certifies that it is the owner of the entire right, title and interest in US Application No. 10/665,520 filed September 22, 2003, by virtue of an Assignment recorded in the US Patent and Trademark Office on June 17, 1998, at Reel 9260, Frame 0797.

Pursuant to 37 CFR § 1.321, Laboratoires Fournier, S.A. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of any patent granted on US Application No. 10/665,520 filed September 22, 2003, and hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent granted on US Application No. 10/665,520 filed September 22, 2003; this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.

Laboratoires Fournier, S.A. does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patent granted on US Application No. 10/665,520 filed September 22, 2003, in the event that any patent granted on US Application No. 10/665,520 filed September 22,

06/21/2006 HALI11 00000069 220261 10665522 01 FC:1814 130.00 DA

Terminal Disclaimer US Application No. 10/665,522 Page 2 of 2

2003, later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.32(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

By:

Edward D. Grieft

Registration No. \$8,898

Venable LLP

575 7th Street, NW

Washington, DC 20004 Phone: 202-344-4382

Fax: 202-344-8300

Date: June 19, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Alagrafie Application of: Stamm et al

Application No. 10/665,522 Group Art Unit: 1615

Filed: September 22, 2003 Examiner: Sheikh

For: Fenofibrate Compositions Having Enhanced Bioavailability

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Information Disclosure Statement

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 Form. A copy of the Non Patent Literature Documents and the Foreign Patent Documents is attached hereto.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents, oppositions and/or litigations are material to patentability or that the listed documents are prior art.

This Information Disclosure Statement is being filed after the mailing date of a first office action on the merits, but before a final office action or a notice of allowance. Accordingly, the Commissioner is authorized to charge the fee of \$180 to Deposit Account No. 22-0261. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account No. 22-0261.

Applicants respectfully request that the PTO return an initialed copy of the PTO-1449 Form with the next communication from the Office.

Respectfully submitted,

06/21/2006 HALI11

00000068 220261

10665522

01 FC:1806 180.00 DA

Edward D. Grieff Registration No. 38,89

Date: June 19, 2006

Venable LLP 575 7th Street, NW

Washington, DC 20004 Phone: 202-344-4382

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for its That

Complete if Known Application Number Filing Date September 22, 2003 First Named Inventor Stamm Art Unit 1615 **Examiner Name** Sheikh

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) Attorney Docket Number of 2

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 6,248,355	06-19-2001	Seth	
		^{US-} 6,159,499	12-12-2000	Seth	
		^{US-} 6,207,198	03-27-2001	Seth	
		^{US-} 4,717,569	01-05-1988	Harrison et al	
		^{US-} 5,783,215	07-21-1998	Arwidson et al	
		US-			
	-	US-			
		US-			
	<u> </u>	US-			
		US-			
		US-			
	<u> </u>	US-			
	<u> </u>	US-			
		US-	-		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T
		WO 96/01621	01-25-1996	Astra Aktiebolag		
						L
						L
					<u> </u>	Ļ
						L
			i	1		١

Examiner		Date	
Signature	· •	Considered	
Q.g=10.0			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10 INFORMATION DISCLOSURE **Filing Date** STATEMENT BY APPLICANT First Named Inventor Stamm Art Unit 1615 (Use as many sheets as necessary) **Examiner Name** Sheikh Attorney Docket Number Sheet 2 of

	 <u>.</u>	NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when Initials* No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pa		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Opposition to European Patent No. 1 273 293 filed 9-2-2005 by Ethypharm. (English Language Translation)	✓
		Laboratoires S.M.B. S.A. Report pages 1-4 (undated)	
		Report from Pr. Rosset entitled "La biodisponibilite du fenofibrate et les polymeres hydrophiles," Pages 1-20 (March 1, 2005)	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: